Carnosine

1. Overview

Carnosine (beta-alanyl-L-histidine) is an endogenous dipeptide first discovered in 1900 by the Russian chemist V.S. Gulevich as an abundant non-protein nitrogen-containing compound isolated from meat extract. It consists of beta-alanine and L-histidine joined by a peptide bond, with a molecular weight of 226.23 g/mol (CAS 305-84-0). Carnosine is found at high concentrations in skeletal muscle (20-30 mmol/kg dry weight), cardiac muscle, and to a lesser extent in the brain (0.5-2 mM), olfactory bulb, stomach, and kidneys of vertebrates [1].

The dipeptide is synthesized intracellularly by carnosine synthase (ATPGD1, ATP-grasp domain-containing protein 1) in a reaction that requires ATP, and is degraded by two carnosinase enzymes: serum carnosinase (CN1, encoded by the CNDP1 gene on chromosome 18q22.3), which is secreted into the blood and specifically hydrolyzes carnosine, and tissue carnosinase (CN2, encoded by CNDP2), a cytoplasmic dipeptidase with broader substrate specificity [1]. The rapid degradation of carnosine by serum CN1 in humans -- with very little intact carnosine detectable in circulation after 4 hours of ingestion -- represents the central pharmacological challenge for oral supplementation [21].

Carnosine has been the subject of over 4,000 published studies documenting a remarkably diverse range of biological activities, including intracellular pH buffering, reactive oxygen species (ROS) scavenging, metal ion chelation, inhibition of advanced glycation end-product (AGE) formation, reactive carbonyl quenching, and neuromodulatory effects. This pluripotent protective profile has made it one of the most extensively researched naturally occurring dipeptides, with clinical investigations spanning exercise physiology, diabetic complications, neurodegeneration, cardiovascular disease, autism spectrum disorders, and aging [1][3][22].

Molecular Weight

226.23 g/mol

Chemical Formula

C9H14N4O3

CAS Number

305-84-0

Structure

Dipeptide of beta-alanine and L-histidine linked by peptide bond

Mechanism

pH buffering, ROS scavenging, metal chelation (Cu2+, Zn2+, Fe2+), AGE inhibition, carbonyl quenching

Endogenous Levels

Skeletal muscle: 20-30 mmol/kg dry weight; brain: 0.5-2 mM

Primary Degradation Enzyme

Serum carnosinase (CN1/CNDP1) on chromosome 18q22.3

Typical Oral Dose (research)

500-2000 mg/day in clinical trials

FDA Status

Available as dietary supplement (GRAS); not approved as drug

2. Mechanism of Action

Carnosine's biological activities derive from the combined physicochemical properties of its two constituent amino acids -- the beta-amino acid beta-alanine and the imidazole-containing L-histidine -- which together confer a set of overlapping and synergistic protective mechanisms [1][3].

pH Buffering

The imidazole ring of the histidine residue has a pKa of approximately 6.83, which falls within the physiological pH range of exercising muscle (pH 6.5-7.1). This makes carnosine an effective intracellular buffer, capable of accepting protons as pH drops during high-intensity exercise. In skeletal muscle, carnosine contributes an estimated 10-20% of total physicochemical buffering capacity, making it the most important non-bicarbonate intracellular buffer [1][7][25]. This buffering role is the primary mechanism underlying the ergogenic effects of beta-alanine supplementation (discussed in Section 3).

Antioxidant Activity and ROS Scavenging

Carnosine is a direct scavenger of hydroxyl radicals (.OH), the most reactive and damaging ROS. The imidazole ring of histidine is the primary reactive center for radical scavenging [20]. Carnosine also scavenges hypochlorous acid (HOCl), singlet oxygen, and peroxyl radicals. However, it does not react meaningfully with superoxide radical or hydrogen peroxide at physiological concentrations [20]. Beyond direct scavenging, carnosine can chelate pro-oxidant transition metal ions (see below), thereby preventing metal-catalyzed ROS generation [1][3].

Metal Ion Chelation

Carnosine binds divalent metal cations including copper (Cu2+), zinc (Zn2+), iron (Fe2+), and cobalt (Co2+) via coordination through its imidazole nitrogen, amino group, and carbonyl oxygen. By chelating redox-active metals such as copper and iron, carnosine prevents Fenton chemistry and metal-catalyzed oxidation of lipids, proteins, and DNA. Zinc chelation may be relevant to its neuromodulatory activity, as zinc is co-released with glutamate at excitatory synapses and can be neurotoxic at high concentrations [1][20].

Anti-Glycation (AGE Inhibition)

One of carnosine's most distinctive properties is its ability to inhibit the formation of advanced glycation end-products (AGEs) through multiple mechanisms [3][5]:

1. Carbonyl quenching: The free amino group of the beta-alanine residue reacts with reactive carbonyl species, including methylglyoxal (MG), glyoxal, and other 1,2-dicarbonyl compounds that are key intermediates in AGE formation. Carnosine acts as a sacrificial nucleophile, forming carnosine-carbonyl adducts rather than allowing these reactive species to modify proteins.

2. Synergistic imidazole stabilization: The neighboring imidazolium moiety of histidine stabilizes the Schiff base formed between carnosine's beta-alanine amino group and dicarbonyl compounds, making carnosine substantially more effective as an AGE inhibitor than beta-alanine alone [3].

3. Transglycation: Carnosine can accept glycation adducts from already-glycated proteins, effectively "deglycating" them via a transglycation reaction.

Neurotransmitter Modulation

In the central nervous system, carnosine may function as a neuromodulator. It is present in glial cells and in subpopulations of neurons, particularly in the olfactory bulb. Evidence suggests roles in modulating glutamatergic neurotransmission (partly via zinc chelation at synapses), influencing GABAergic signaling (homocarnosine, the brain-specific analog, is synthesized from GABA and histidine), and activating histamine receptors after hydrolysis to its constituent amino acids. Carnosine also enhances brain Na,K-ATPase activity and protects against hydrogen peroxide-induced loss of this enzyme function [1][23].

3. Researched Applications

Exercise Performance and Muscle Buffering

Evidence level: Strong clinical (via beta-alanine supplementation)

Because beta-alanine is the rate-limiting precursor for carnosine synthesis, and direct oral carnosine is rapidly degraded by serum carnosinase, the primary strategy for increasing muscle carnosine stores is beta-alanine supplementation. Four weeks of beta-alanine at 4-6 g/day increases muscle carnosine by 30-80% [7][25]. In the landmark Derave et al. (2007) study of 400m sprint-trained athletes, 4.8 g/day for 4 weeks increased carnosine in the soleus (+47%) and gastrocnemius (+37%), and significantly improved dynamic knee extension torque during repeated high-intensity bouts [7].

The Hobson et al. (2012) meta-analysis of 15 studies (360 participants) found that beta-alanine supplementation produced a median 2.85% improvement in exercise outcomes, with significant benefits for exercise lasting 60-240 seconds and beyond 240 seconds, but no benefit for exercise lasting under 60 seconds [8]. The International Society of Sports Nutrition (2015) position stand concluded that beta-alanine supplementation (4-6 g/day for at least 2-4 weeks) is an effective ergogenic aid for high-intensity exercise, primarily through increased muscle carnosine and enhanced intracellular pH buffering [25].

Diabetic Complications

Evidence level: Clinical trials (multiple RCTs)

Carnosine has been investigated across the spectrum of diabetic complications owing to its combined anti-glycation, antioxidant, and anti-inflammatory properties.

Diabetic Nephropathy: The Elbarbary et al. (2018) randomized placebo-controlled trial in 90 pediatric patients with type 1 diabetes and nephropathy demonstrated that 12 weeks of carnosine 1 g/day significantly reduced HbA1c (8.2% to 7.4%), urinary albumin excretion (91.7 to 38.5 mg/g creatinine), and oxidative stress markers while increasing total antioxidant capacity (all P < .001 vs placebo) [4]. This protective effect is further supported by genetic evidence: the CNDP1 5-leucine repeat polymorphism, which produces lower serum carnosinase activity and thus higher circulating carnosine, is associated with significantly reduced risk of diabetic end-stage renal disease in European Americans [11][12].

Diabetic Neuropathy: A 2024 randomized controlled trial showed that carnosine combined with vitamin B complex significantly improved nerve growth factor levels and reduced neuropathic symptoms compared to vitamin B complex alone after 12 weeks, with decreased inflammatory and oxidative stress markers [17].

Diabetic Retinopathy: In animal models, oral carnosine supplementation for 6 months prevented retinal vascular damage and protected retinal capillary cells from hyperglycemia-induced injury [16]. Carnosine improved retinopathy via the MAPK/ERK pathway in rat models. Human clinical trials for retinopathy remain limited.

Glucose Metabolism: In the de Courten et al. (2016) pilot trial in 30 overweight/obese nondiabetic adults, carnosine 2 g/day for 12 weeks prevented the rise in fasting insulin and insulin resistance (HOMA-IR) seen in the placebo group (P = 0.02) [6]. The Houjeghani et al. (2018) trial in 44 type 2 diabetes patients found that carnosine 1 g/day for 12 weeks significantly reduced fasting glucose (-13.1 mg/dL), HbA1c (-0.6%), triglycerides (-29.8 mg/dL), AGEs (CML -91.8 ng/mL), and TNF-alpha [5].

Neuroprotection

Evidence level: Preclinical (strong animal data); limited clinical

Carnosine demonstrates robust neuroprotective effects across multiple preclinical models of neurodegeneration and brain injury [23]:

Alzheimer's Disease: In AD animal models, oral carnosine reduced amyloid-beta (Abeta) accumulation and tau hyperphosphorylation, decreased neuroinflammatory markers and oxidative damage, and improved cognitive function. The neuroprotective effect is partly mediated by insulin-degrading enzyme, which degrades both insulin and Abeta [23].

Parkinson's Disease: Intranasal carnosine (approximately 2-4 mg/day for 8 weeks) significantly improved motor function and reduced alpha-synuclein aggregation in transgenic PD mouse models. Systemic carnosine injections in toxin-based Parkinsonian models attenuated dopaminergic neuron loss and elevated antioxidant enzyme levels [23].

Ischemic Stroke: A systematic review and meta-analysis of 29 comparisons in animal stroke models found that carnosine reduced infarct volume by 29.4% (95% CI: 24.0-34.9%), with greatest efficacy at 1000 mg/kg and when administered within 6 hours of ischemia onset [13].

Cognitive Function (Human): The NEAT trial (2025) found that carnosine 2 g/day for 12 weeks significantly improved cognitive speed and efficiency in younger adults (23-35 years), with improvements in 7 individual test domains, though older age groups showed minimal benefit [18]. A separate 2025 RCT in adults with prediabetes and well-controlled type 2 diabetes also demonstrated improved cognitive outcomes with carnosine supplementation, supporting a neuroprotective role in metabolically at-risk populations [26].

Autism Spectrum Disorders

Evidence level: Mixed/inconclusive clinical

The Chez et al. (2002) double-blind placebo-controlled trial in 31 children with ASD found that 800 mg/day L-carnosine for 8 weeks produced statistically significant improvements on the Gilliam Autism Rating Scale (GARS) total score and subscales (Behavior, Socialization, Communication), and the Receptive One-Word Picture Vocabulary test (P < .05) [9]. However, a 2021 meta-analysis of three RCTs found no significant differences between carnosine and placebo on GARS or CARS scores, though carnosine significantly reduced sleep disorder scores by 7.59% [24]. Current evidence is insufficient to support carnosine for ASD management.

Anti-Aging and Longevity

Evidence level: Preclinical (in vitro and animal)

Alan R. Hipkiss and colleagues have proposed carnosine as a geroprotector based on its ability to counteract the glycation-oxidative stress axis of aging [2][3][15]. Key findings include:

• Carnosine delays senescence in cultured human fibroblasts and extends lifespan in senescence-accelerated mice and Drosophila [15][22].
• Cells grown continuously in 20 mM carnosine exhibited slower telomere shortening rates and extended population doubling lifespan [14].
• Hipkiss's theoretical framework links carnosine to the resolution of the "oxygen paradox" of aging: low NAD+ increases methylglyoxal from glycolytic triose phosphates, which damages proteins and mitochondria. Carnosine's methylglyoxal-scavenging activity directly interrupts this cascade [15].
• A 2024 geroscience review identified carnosine as a candidate geroprotector with evidence across multiple hallmarks of aging, including cellular senescence, mitochondrial dysfunction, and chronic inflammation [22].

Cardiovascular Protection

Evidence level: Preclinical (animal and in vitro)

Carnosine protects cardiac myocytes against lipid peroxidation products including 4-hydroxynonenal (HNE) and acrolein by directly reacting with these toxic aldehydes [19]. In the heart, carnosine's physiological roles include regulation of calcium handling and sensitivity, ROS quenching, reactive aldehyde detoxification, and transition metal chelation [19]. Carnosine levels are decreased in failing hearts, and beta-alanine supplementation (to increase cardiac carnosine) decreased left ventricular mass and improved ejection fraction and cardiac output in animal models of heart failure after 8 weeks of transaortic constriction [19]. In patients with heart failure with reduced ejection fraction (HFrEF), low carnosinase-1 activity has been observed, which may represent an adaptive mechanism to preserve carnosine levels and suggests oral carnosine therapy could be particularly beneficial in this population.

Ophthalmic Use (N-Acetylcarnosine)

Evidence level: Limited/disputed clinical

N-acetylcarnosine (NAC) eye drops have been proposed for cataract treatment based primarily on research by Babizhayev and colleagues. A 2002 trial in 49 subjects (76 eyes) with senile cataract reported that 1% NAC eye drops applied twice daily for 6 months improved best corrected visual acuity in 90% of treated eyes and glare sensitivity in 88.9%, with sustained benefits at 24 months [10]. However, a 2017 Cochrane systematic review concluded there is "no convincing evidence that NAC reverses cataract, nor prevents progression of cataract," and excluded the Babizhayev studies due to methodological concerns. The results have not been independently replicated [10].

4. Clinical Evidence Summary

5. Dosing in Research

The following table summarizes doses used in published clinical and preclinical studies. These represent research protocols and are not therapeutic recommendations.

Key pharmacokinetic considerations: Oral carnosine is rapidly absorbed (peak plasma at approximately 15 minutes for moderate doses) but is extensively degraded by serum carnosinase (CN1), with very little intact carnosine detectable in circulation after 4 hours [21]. Brain carnosine concentrations increased 1 hour post-dose but returned to baseline by 5 hours [21]. This rapid degradation has led researchers to explore alternative strategies including beta-alanine supplementation (to increase endogenous muscle carnosine synthesis), N-acetylcarnosine (as a prodrug resistant to carnosinase), and sustained-release formulations.

6. Pharmacokinetics

Oral Absorption and Carnosinase Degradation

The central pharmacokinetic challenge for oral carnosine is its rapid degradation by serum carnosinase (CN1/CNDP1). After oral ingestion, carnosine is absorbed intact from the small intestine into portal circulation, where it is immediately exposed to high CN1 activity. The 2025 phase I study by Oppermann et al. established key PK parameters in healthy volunteers [21]:

• Time to peak plasma concentration (Tmax): Approximately 15 minutes after a 4 g oral dose, indicating rapid absorption [21].
• Plasma half-life: Very short; intact carnosine becomes largely undetectable in circulation within 4 hours of ingestion [21].
• Brain penetration: Brain carnosine concentrations (measured by MRS) increased at 1 hour post-dose but returned to baseline by 5 hours [21].
• Dose-proportionality: Higher oral doses produce higher but still transient peak plasma levels, with the same rapid clearance kinetics.

Effective Bioavailability

The effective systemic bioavailability of intact carnosine after oral dosing has been estimated at approximately 14% after accounting for carnosinase degradation [1]. The majority of an oral dose is hydrolyzed to beta-alanine and histidine by CN1 in plasma and CN2 in tissues. While these constituent amino acids are themselves bioactive (beta-alanine for muscle carnosine resynthesis; histidine as a histamine precursor), the unique properties of the intact dipeptide -- particularly its superior anti-glycation and carbonyl-quenching activities -- are lost upon hydrolysis [3].

Genetic Determinants of Bioavailability

The CNDP1 gene (chromosome 18q22.3) contains a variable number of leucine (CTG) repeats in exon 2 that directly determine serum carnosinase activity [11][12]:

• 5-leucine repeat homozygous (5L-5L): Lowest carnosinase activity; highest carnosine bioavailability. Associated with reduced diabetic nephropathy risk (2-fold protection in women) [11][12].
• 6-leucine or longer repeats: Higher carnosinase activity; lower circulating carnosine after oral dosing.
• Population differences: The 5L-5L genotype frequency varies by ethnicity, contributing to population-level differences in carnosine supplementation efficacy.

Alternative Delivery Strategies

Several strategies have been developed to circumvent the carnosinase barrier:

• Beta-alanine supplementation: Bypasses systemic carnosinase entirely by providing the rate-limiting precursor for intracellular carnosine synthesis. 4-6 g/day for 4 weeks increases muscle carnosine by 30-80% [7][25]. This is the most pharmacokinetically robust approach for increasing muscle carnosine stores.
• N-acetylcarnosine (NAC): A carnosinase-resistant prodrug used as 1% ophthalmic drops. Resists CN1 hydrolysis in the aqueous humor; deacetylated to release carnosine in target tissue [10].
• Sustained-release formulations: Under investigation to maintain plasma carnosine levels above the carnosinase degradation threshold for longer periods.
• High-dose oral loading: The 2025 PK study showed that single doses up to 10 g are safe and tolerated [21], and higher doses may temporarily overwhelm carnosinase capacity, producing transiently higher intact carnosine exposure.

Tissue Distribution

Endogenous carnosine concentrations vary dramatically by tissue:

• Skeletal muscle: 20-30 mmol/kg dry weight (highest concentration; primary reservoir) [1].
• Cardiac muscle: Similar concentrations to skeletal muscle; carnosine is decreased in failing hearts [19].
• Brain: 0.5-2 mM; concentrated in olfactory bulb and glial cells [1].
• Plasma: Very low (less than 1 mcM fasting) due to CN1 activity; transiently elevated after oral dosing [21].
• Kidney: Moderate concentrations; relevant to renoprotective effects.

7. Dose-Response Relationships

Exercise Performance (via Beta-Alanine)

The dose-response for exercise performance operates indirectly through beta-alanine supplementation and muscle carnosine loading:

• Muscle carnosine loading: 4-6 g/day beta-alanine for 4 weeks increases muscle carnosine by 30-80%. Derave et al. (2007) found +47% in soleus and +37% in gastrocnemius [7]. The loading relationship is approximately linear up to 6 g/day, with diminishing returns beyond 10-12 weeks [25].
• Exercise duration dependency: The Hobson et al. (2012) meta-analysis established a clear dose-response based on exercise duration [8]:
  • Exercise lasting less than 60 seconds: No significant benefit (effect size ~0.1).
  • Exercise lasting 60-240 seconds: Significant benefit (median effect size 0.374, median improvement 2.85%).
  • Exercise lasting more than 240 seconds: Significant benefit, likely through multiple buffering mechanisms.
• Cumulative dose: The median total beta-alanine dose across studies showing benefit was 179 g (approximately 4.5 weeks at 5.7 g/day) [8].
• Sustained-release advantage: Paresthesia (tingling) is the main side effect of beta-alanine and is dose-rate dependent, occurring at single servings above 800 mg. Sustained-release formulations eliminate paresthesia while achieving equivalent muscle carnosine loading [25].

Cognitive Function

The NEAT trial (2025) revealed an age-dependent dose-response for cognitive effects of carnosine 2 g/day [18]:

• Young adults (23-35 years): Significant improvements in overall speed and efficiency at both 6- and 12-week follow-ups, with improvements across 7 individual test domains.
• Middle-aged adults (36-55 years): Few significant improvements.
• Older adults (56+ years): No significant improvements.
• This inverse age-response may reflect the higher carnosinase activity and lower baseline brain carnosine in older individuals, suggesting that older adults may require higher doses or carnosinase-resistant formulations.

Diabetic Complications

A dose-response pattern emerges across the diabetes clinical trial literature:

• 1 g/day (12 weeks): Elbarbary et al. (2018) -- significant reductions in HbA1c (8.2% to 7.4%), urinary albumin (91.7 to 38.5 mg/g creatinine), and oxidative stress markers in pediatric diabetic nephropathy (all P less than .001 vs. placebo) [4]. Houjeghani et al. (2018) -- significant reductions in fasting glucose (-13.1 mg/dL), HbA1c (-0.6%), triglycerides (-29.8 mg/dL), and AGEs in T2D (P significant vs. placebo) [5].
• 2 g/day (12 weeks): de Courten et al. (2016) -- prevented rise in fasting insulin and HOMA-IR in overweight/obese nondiabetic adults (P = 0.02 and P = 0.04 vs. placebo) [6]. In the impaired glucose tolerance subgroup, 2-hour glucose and insulin were significantly lower.
• Dose comparison: No head-to-head dose-finding studies have been published. The available evidence suggests 1 g/day is effective for established diabetic complications, while 2 g/day may be needed for metabolic prevention in at-risk populations.

Neuroprotection (Preclinical)

In the animal stroke meta-analysis (Davis et al. 2016), carnosine reduced infarct volume by 29.4% (95% CI: 24.0-34.9%) [13]:

• Optimal dose: Greatest efficacy at 1000 mg/kg in rodent models.
• Timing dependency: Treatment most effective when administered within 6 hours of ischemia onset.
• Intranasal carnosine for PD: 2-4 mg/day for 8 weeks improved motor function in transgenic mouse models [23].

8. Comparative Effectiveness

Oral Carnosine vs. Beta-Alanine Supplementation

This is the most clinically relevant comparison, as both strategies aim to increase tissue carnosine levels:

| Feature | Oral Carnosine | Beta-Alanine | |---------|---------------|--------------| | Mechanism | Direct carnosine supply | Provides rate-limiting precursor for endogenous synthesis | | Muscle carnosine increase | Modest (~15-20% at 2 g/day) | Robust (30-80% at 4-6 g/day for 4 weeks) [7] | | Carnosinase barrier | Major limitation (~14% survives CN1) | Bypassed entirely (intracellular synthesis) | | Systemic carnosine | Transiently elevated (peak at 15 min) | Not significantly changed | | Brain effects | Measurable at 1 hour post-dose [21] | Minimal brain carnosine increase (beta-alanine does not readily cross BBB) | | Anti-glycation (systemic) | Active while intact carnosine circulates | Limited (muscle carnosine does not circulate) | | Exercise performance | Minimal direct evidence | Strong meta-analytic evidence (2.85% improvement) [8] | | Side effects | Well tolerated up to 10 g [21] | Paresthesia (tingling) at doses more than 800 mg/serving [25] | | Cost | Moderate ($0.50-1.50/g) | Low ($0.10-0.30/g) | | ISSN recommendation | Not specifically addressed | Endorsed as ergogenic aid [25] |

Interpretation: For exercise performance and muscle carnosine loading, beta-alanine is pharmacokinetically superior. For systemic anti-glycation, antioxidant, and potential neuroprotective effects requiring intact circulating carnosine, direct carnosine supplementation (or carnosinase-resistant analogs) may be preferable.

Oral Carnosine vs. NAC Eye Drops

For ophthalmic use, the comparison is between systemic oral carnosine and topical N-acetylcarnosine (NAC):

• Oral carnosine for ocular benefit: No clinical evidence supports oral carnosine supplementation for cataract treatment. Systemic carnosine is degraded before reaching therapeutically relevant ocular concentrations.
• 1% NAC eye drops (Babizhayev et al. 2002): Reported 90% improvement in visual acuity and 88.9% improvement in glare sensitivity after 6 months in 49 cataract patients [10]. NAC resists carnosinase in the aqueous humor and delivers carnosine directly to the lens.
• Cochrane review (2017): Found "no convincing evidence" that NAC reverses or prevents cataracts and excluded the Babizhayev studies due to methodological concerns. The results have not been independently replicated.
• Verdict: NAC eye drops remain controversial. Oral carnosine is not a substitute for topical delivery for ophthalmic indications.

Carnosine vs. Aminoguanidine (AGE Inhibition)

Aminoguanidine (pimagedine) was the first pharmacological AGE inhibitor studied clinically:

• Mechanism: Both carnosine and aminoguanidine react with reactive carbonyl intermediates. Aminoguanidine traps dicarbonyl compounds; carnosine acts as a sacrificial nucleophile with additional synergistic imidazole stabilization [3].
• Clinical development: Aminoguanidine reached phase III trials for diabetic nephropathy (ACTION I and ACTION II) but was terminated due to safety concerns (vitamin B6 depletion, autoimmune-like reactions, GI toxicity).
• Safety advantage: Carnosine is an endogenous compound with GRAS status and an excellent safety profile up to 10 g single dose [21]. This safety advantage is a major differentiator.

Carnosine vs. Alpha-Lipoic Acid (Diabetic Neuropathy)

Both are investigated for diabetic neuropathy with antioxidant mechanisms:

• Alpha-lipoic acid: 600 mg IV daily for 3 weeks improved neuropathic symptoms in the ALADIN and SYDNEY trials. Oral 600 mg/day also shows benefit.
• Carnosine: 1 g/day plus vitamin B complex improved NGF levels and neuropathic symptoms vs. vitamin B alone [17].
• Head-to-head: No direct comparisons exist. Both may work through complementary antioxidant pathways.

9. Safety and Side Effects

Human Safety Data (Quantitative)

The 2025 phase I study (Oppermann et al.) provides the most comprehensive safety dataset for oral carnosine in healthy volunteers [21]:

Single-dose escalation:

• 1 g single dose: 0% adverse event rate.
• 4 g single dose: Minimal adverse events; well tolerated.
• 10 g single dose: Safe and well tolerated with minimal adverse events. No serious adverse events.
• 15 g single dose: 77% adverse event rate. Headache in 43.5% of participants. This defines the upper boundary of single-dose tolerance.
• No-observed-adverse-effect level (NOAEL): 10 g single dose in healthy volunteers [21].

Chronic dosing:

• 5 g twice daily (multi-week): Zero adverse events reported during extended supplementation [21].
• 2 g/day for 12 weeks (NEAT trial, n=242-299): No significant adverse events [18].
• 1 g/day for 12 weeks (pediatric diabetic nephropathy, n=45): No significant adverse events [4].
• 1 g/day for 12 weeks (T2D, n=22): No significant adverse events [5].
• 2 g/day for 12 weeks (overweight/obese, n=15): No significant adverse events [6].
• 800 mg/day for 8 weeks (pediatric ASD, n=16): No significant adverse events [9].

Aggregate clinical trial safety (across all published RCTs):

• Total subjects receiving carnosine in published RCTs: approximately 350-400.
• Serious adverse events attributable to carnosine: zero across all published trials.
• Treatment discontinuation due to adverse events: not reported in any trial.
• Laboratory abnormalities: no significant changes in hepatic, renal, or hematological parameters in monitored studies.

Known Side Effects

At typical supplemental doses (500-2000 mg/day), carnosine has an excellent safety profile. Potential side effects at higher doses include headache, gastrointestinal discomfort, and transient paresthesia (tingling), the latter of which is more commonly associated with beta-alanine supplementation (especially at doses above 800 mg per individual serving) rather than carnosine itself.

Drug Interactions

No significant drug interactions have been documented in published clinical trials. Theoretical interactions include: potential additive effects with antidiabetic medications (given carnosine's glucose-lowering properties), potential interactions with metal chelation therapies, and possible interactions with antihypertensive agents. Patients on medication should consult a healthcare provider.

Contraindications and Precautions

• Carnosinase deficiency (carnosinemia): Rare genetic condition resulting in elevated serum carnosine; supplementation is contraindicated.
• Pregnancy and lactation: No safety data available; not recommended.
• Pediatric use: Limited to clinical trial settings (e.g., Elbarbary 2018 at 1 g/day in diabetic nephropathy) [4].
• Histidine sensitivity: Carnosine is hydrolyzed to histidine, which is a precursor for histamine. Individuals with histamine intolerance should use caution, though this interaction has not been documented in clinical trials.

Carnosinase (CN1/CNDP1) Polymorphisms and Individual Variability

Genetic variation in the CNDP1 gene -- specifically the number of leucine (CTG) repeats in exon 2 -- significantly affects serum carnosinase activity and thereby the bioavailability and efficacy of carnosine [11][12]. The 5-leucine repeat homozygous genotype (5L-5L) is associated with lower carnosinase activity and higher circulating carnosine levels. This polymorphism has clinical significance: 5L-5L homozygosity confers significant protection against diabetic nephropathy in European and European American populations, with a particularly strong sex-specific effect in women (twofold reduced risk) [11][12]. The association has not been replicated in African American populations, suggesting ethnic-specific effects.

10. Related Compounds

Anserine (beta-Alanyl-N-pi-methyl-L-histidine)

Anserine is the methylated analog of carnosine found predominantly in avian and fish muscle. It shares antioxidant and pH-buffering properties with carnosine but is degraded more slowly by carnosinase, giving it superior bioavailability when co-administered with carnosine [20]. Most non-human animals possess either anserine or ophidine/balenine in addition to carnosine [1].

Homocarnosine (gamma-Aminobutyryl-L-histidine)

Homocarnosine is a mammal-specific histidyl dipeptide found primarily in the central nervous system, synthesized from GABA and histidine. It shares hydroxyl radical scavenging activity with carnosine and can activate brain Na,K-ATPase, but unlike carnosine, it has no effect on iron-dependent lipid peroxidation [20]. Its brain-specific distribution and GABA component suggest distinct neuromodulatory functions.

N-Acetylcarnosine

N-acetylcarnosine is a carnosine derivative resistant to serum carnosinase hydrolysis. It has been investigated primarily as a topical ophthalmic prodrug that delivers carnosine to the lens for cataract treatment [10]. Once in the aqueous humor, it is deacetylated to release carnosine.

See also: BPC-157, Glutathione, Epitalon, Selank, Semax

11. References

1. [1] Boldyrev AA, Aldini G, Derave W. (2013). Physiology and Pathophysiology of Carnosine. Physiological Reviews. DOI PubMed
2. [2] Hipkiss AR, Brownson C, Carrier MJ. (2001). Carnosine, the anti-ageing, anti-oxidant dipeptide, may react with protein carbonyl groups. Mechanisms of Ageing and Development. DOI PubMed
3. [3] Hipkiss AR. (2005). Carnosine: A Versatile Antioxidant and Antiglycating Agent. Science of Aging Knowledge Environment. DOI PubMed
4. [4] Elbarbary NS, Ismail EAR, El-Naggar AR, Hamouda MH, El-Hamamsy M. (2018). The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial. Pediatric Diabetes. DOI PubMed
5. [5] Houjeghani S, Kheirouri S, Faraji E, Jafarabadi MA. (2018). L-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-alpha levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial. Nutrition Research. DOI PubMed
6. [6] de Courten B, Jakubova M, de Courten MP, Kukurova IJ, Vallova S, Krumpolec P, Valkovic L, Kurdiova T, Garber A, Komber E, Ukropec J, Ukropcova B, Aldini G, Pischetsrieder M, Zulli A. (2016). Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. Obesity. DOI PubMed
7. [7] Derave W, Ozdemir MS, Harris RC, Pottier A, Reyngoudt H, Koppo K, Wise JA, Achten E. (2007). beta-Alanine supplementation augments muscle carnosine content and attenuates fatigue during repeated isokinetic contraction bouts in trained sprinters. Journal of Applied Physiology. DOI PubMed
8. [8] Hobson RM, Saunders B, Ball G, Harris RC, Sale C. (2012). Effects of beta-alanine supplementation on exercise performance: a meta-analysis. Amino Acids. DOI PubMed
9. [9] Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Schaefer K, Black C, Komen J. (2002). Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. Journal of Child Neurology. DOI PubMed
10. [10] Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Doroshenko VS, Zhukotskii AV, Goldman IM. (2002). Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs in R&D. DOI PubMed
11. [11] Freedman ND, Janssen I, Sims CR, et al. (2007). A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. Journal of Clinical Investigation. DOI PubMed
12. [12] Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rber N, Krber C, Nocber I, Grabber I, Mehls O, Janssen Bl, et al. (2010). Association between CNDP1 genotype and diabetic nephropathy is sex specific. Diabetes. DOI PubMed
13. [13] Davis CK, Laud PJ, Bahor Z, Rajanikant GK, Majid A. (2016). Systematic review and stratified meta-analysis of the efficacy of carnosine in animal models of ischemic stroke. Journal of Cerebral Blood Flow and Metabolism. DOI PubMed
14. [14] Shao L, Li QH, Tan Z. (2004). L-Carnosine reduces telomere damage and shortening rate in cultured normal fibroblasts. Biochemical and Biophysical Research Communications. DOI PubMed
15. [15] Hipkiss AR. (2010). Aging, Proteotoxicity, Mitochondria, Glycation, NAD+ and Carnosine: Possible Inter-Relationships and Resolution of the Oxygen Paradox. Frontiers in Aging Neuroscience. DOI PubMed
16. [16] Pfister F, Riedl E, Wang Q, vom Hagen F, Deinzer M, Harmsen MC, Molema G, Yard B, Feng Y, Hammes HP. (2011). Oral carnosine supplementation prevents vascular damage in experimental diabetic retinopathy. Cellular Physiology and Biochemistry. DOI PubMed
17. [17] El-Reshaid K, Al-Bader S, Goyens P. (2024). Effect of Carnosine Supplementation as Add-On Therapy With Vitamin B Complex in People With Type 2 Diabetes and Diabetic Neuropathy. Clinical Diabetes. DOI PubMed
18. [18] Regazzoni L, Hohenester UM, Bhargava P, et al. (2025). Carnosine supplementation improves cognitive outcomes in younger participants of the NEAT trial. Nutritional Neuroscience. DOI PubMed
19. [19] Cararo JH, Streck EL, Seroogy KB, et al. (2022). Physiological Roles of Carnosine in Myocardial Function and Health. Advances in Nutrition. DOI PubMed
20. [20] Kohen R, Yamamoto Y, Cundy KC, Ames BN. (1988). Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proceedings of the National Academy of Sciences. DOI PubMed
21. [21] Oppermann H, Birkner K, Gaunitz F, et al. (2025). Dietary Carnosine Supplementation in Healthy Human Volunteers: A Safety, Tolerability, Plasma and Brain Concentration Study. Nutrients. DOI PubMed
22. [22] Menon K, Marquina C, Liew D, Mousa A, de Courten B. (2024). Carnosine and Its Therapeutic Potential. Maturitas. DOI PubMed
23. [23] Caruso G, Torrisi SA, Privitera A, et al. (2025). Preclinical evidence and therapeutic perspectives on carnosine for the treatment of neurodegenerative disorders. AIMS Neuroscience. DOI PubMed
24. [26] Menon K, et al. (2025). Effects of Carnosine Supplementation on Cognitive Outcomes in Prediabetes and Well-Controlled Type 2 Diabetes: A Randomised Placebo-Controlled Clinical Trial. Pharmaceuticals. DOI PubMed
25. [24] Mahmoud AM, Ali MM. (2021). Effect of L-Carnosine in children with autism spectrum disorders: a systematic review and meta-analysis of randomised controlled trials. Amino Acids. DOI PubMed
26. [25] Saunders B, Elliott-Sale K, Artioli GG, et al. (2015). International society of sports nutrition position stand: Beta-Alanine. Journal of the International Society of Sports Nutrition. DOI PubMed